 Based on the review of approximately 460 patients, Data Safety and Monitoring Board DSMB determined that the evaluation of NRx Pharmaceuticals Incs NASDAQ: NRXP Zyesami aviptadil should cease due to futility. Aviptadil was the sole remaining investigational medicine in. 